文献速递胸部肿瘤

纳武利尤单抗联合卡铂、紫杉醇及贝伐珠单抗一线治疗晚期非鳞非小细胞肺癌

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2021-06-15

这项国际随机双盲III期研究(ONO-4538-52/TASUKI-52)评估纳武利尤单抗联合贝伐珠单抗及细胞毒化疗一线治疗非鳞非小细胞肺癌的疗效与安全性。研究纳入550例无EGFR/ALK/ROS1敏感突变的初治IIIB/IV期或复发非鳞NSCLC患者,主要终点为独立影像评审委员会评估的无进展生存期。中位随访13.7个月时,纳武利尤单抗组中位PFS显著优于安慰剂组(12.1 vs 8.1个月;HR 0.56;96.4%CI 0.43-0.71;P<0.0001),且各PD-L1表达水平(含阴性)患者均获益。

要点

  • 纳武利尤单抗联合化疗及贝伐珠单抗一线治疗非鳞NSCLC,中位PFS 12.1个月,显著优于安慰剂组的8.1个月。
  • PFS获益在所有PD-L1表达水平患者中均观察到,包括PD-L1阴性患者。
  • 3/4级治疗相关不良事件发生率两组相当,治疗相关死亡分别为5例(纳武利尤单抗组)和4例(安慰剂组)。

核心结论

  • TASUKI-52方案应被视为晚期非鳞NSCLC初治患者的一种可行新治疗策略。

研究设计与样本

  • 国际随机双盲III期研究(ONO-4538-52/TASUKI-52),2017年6月至2019年7月入组550例初治IIIB/IV期或复发非鳞NSCLC患者,无EGFR/ALK/ROS1敏感突变,1:1随机接受纳武利尤单抗或安慰剂联合卡铂、紫杉醇及贝伐珠单抗。

主要发现

  • 中位随访13.7个月,IRRC评估的中位PFS纳武利尤单抗组12.1个月 vs 安慰剂组8.1个月(HR 0.56;96.4%CI 0.43-0.71;P<0.0001)。
  • IRRC评估的客观缓解率纳武利尤单抗组61.5%,安慰剂组50.5%。
  • PFS获益在所有PD-L1表达水平患者中均观察到,包括PD-L1阴性患者。
  • 3/4级治疗相关不良事件发生率两组相当;治疗相关死亡纳武利尤单抗组5例,安慰剂组4例。

临床怎么用

  • 对于无EGFR/ALK/ROS1敏感突变的晚期非鳞NSCLC初治患者,可考虑纳武利尤单抗联合卡铂、紫杉醇及贝伐珠单抗方案。
  • 该方案在各PD-L1表达水平(含阴性)患者中均显示PFS获益,选择患者时可不依赖PD-L1表达状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Between June 2017 and July 2019, this study enrolled treatment-naïve patients with stage IIIB/IV or recurrent nonsquamous NSCLC without sensitizing EGFR, ALK, or ROS1 alterations. They were randomly assigned in a 1 : 1 ratio to receive nivolumab or placebo in combination with carboplatin, paclitaxel, and bevacizumab every 3 weeks for up to six cycles, followed by nivolumab/placebo with bevacizumab until progressive disease or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) assessed by an independent radiology review committee (IRRC). RESULTS: Overall, 550 patients from Japan, Korea, and Taiwan were randomized; of these patients, 273 and 275 received the nivolumab and placebo combinations, respectively. In the present preplanned interim analysis with a median follow up of 13.7 months, the IRRC-assessed median PFS was significantly longer in the nivolumab arm than in the placebo arm (12.1 versus 8.1 months; hazard ratio 0.56; 96.4% confidence interval 0.43-0.71; P < 0.0001). The PFS benefit was observed across all patients with any programmed death-ligand 1 (PD-L1) expression levels including PD-L1-negative patients. The IRRC-assessed objective response rates were 61.5% and 50.5% in the nivolumab and placebo arms, respectively. The incidence of treatment-related adverse events of grade 3 or 4 was comparable between the two arms; treatment-related adverse events leading to death were observed in five and four patients in the nivolumab and placebo arms, respectively. CONCLUSION: The TASUKI-52 regimen should be considered a viable new treatment strategy for treatment-naïve patients with advanced nonsquamous NSCLC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sugawara S, Lee JS, Kang JH, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021. PMID: 34139272. doi:10.1016/j.annonc.2021.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。